During the past decade, CHU Morvan conducted 127 clinical trials. In the 10-year time frame, 127 clinical trials started and 40 clinical trials were completed, i.e. on average, 31.5% percent of trials that started reached the finish line to date. In the past 5 years, 62 clinical trials started and 28 clinical trials were completed. i.e. 45.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU Morvan" #1 sponsor was "UNICANCER" with 11 trials, followed by "Hoffmann-La Roche" with 10 trials sponsored, "Groupe Francais De Pneumo-Cancerologie" with 9 trials sponsored, "Celgene" with 8 trials sponsored and "ARCAGY/ GINECO GROUP" with 8 trials sponsored. Other sponsors include 153 different institutions and companies that sponsored additional 93 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU Morvan" #1 collaborator was "AstraZeneca" with 7 trials as a collaborator, "Bristol-Myers Squibb" with 5 trials as a collaborator, "Ministry of Health, France" with 4 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 3 trials as a collaborator and "Hoffmann-La Roche" with 3 trials as a collaborator. Other collaborators include 83 different institutions and companies that were collaborators in the rest 78 trials.

According to Clinical.Site data, the most researched conditions in "CHU Morvan" are "Breast Cancer" (14 trials), "Multiple Myeloma" (10 trials), "Atopic Dermatitis" (6 trials), "Myelodysplastic Syndromes" (5 trials) and "Prostate Cancer" (5 trials). Many other conditions were trialed in "CHU Morvan" in a lesser frequency.

Most popular intervention types in "CHU Morvan" are "Drug" (144 trials), "Other" (22 trials), "Biological" (14 trials), "Procedure" (10 trials) and "Radiation" (9 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Docetaxel" (8 trials), "Rituximab" (8 trials), "Trastuzumab" (7 trials) and "Cyclophosphamide" (6 trials). Other intervention names were less common.

The vast majority of trials in "CHU Morvan" are 168 trials for "All" genders, 24 trials for "Female" genders and 11 trials for "Male" genders.

Currently, there are NaN active trials in "CHU Morvan". 2 are not yet recruiting, 51 are recruiting, 31 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 91 completed trials in CHU Morvan, undefined suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in CHU Morvan, 10 "Phase 1" clinical trials were conducted, 55 "Phase 2" clinical trials and 90 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 27 trials that are defined as “Not Applicable".